Last reviewed · How we verify
Sevoflurane - Neostigmine 50
Sevoflurane - Neostigmine 50, marketed by Pontificia Universidade Catolica de Sao Paulo, holds a position in the anesthetic and neuromuscular blocking agents market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Sevoflurane - Neostigmine 50 |
|---|---|
| Also known as | Inhalational anesthesia |
| Sponsor | Pontificia Universidade Catolica de Sao Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Mid-transverse Process to Pleura Block in Pediatric Thoracotomy (NA)
- Total Knee Replacement TIVA With Robotic Arm Assisted (PHASE4)
- Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade (PHASE4)
- Microaspiration in ERCP
- Different Concentrations of Bupivacaine in Erector Spinae Plane Block in Hip Surgeries (NA)
- Comparing Reversal With Neostigmine and Sugammadex in Paediatric (NA)
- Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: